Dr. Bradley on the Background of the RTOG 0617 Study

Video

In Partnership With:

Jeffrey D. Bradley, MD, Professor, Radiation Oncology, Washington University School of Medicine in St. Louis, discusses the background of the phase III RTOG 0617 study.

Jeffrey D. Bradley, MD, Professor, Radiation Oncology, Washington University School of Medicine in St. Louis, discusses the background of the phase III RTOG 0617 study.

In the phase III randomized trial, patients with stage III non-small cell lung cancer were randomized to high-dose (74 Gy) or standard-dose (60 Gy) chemoradiotherapy with or without cetuximab. Patients were divided into four arms in a 2x2 factorial design.

The second randomization in this trial was for patients to be given cetuximab during and after radiation therapy. At the 2013 American Society of Clinical Oncology Meeting, Bradley presented on the first randomization -- the radiation dose question.

<<<

View more from the 2013 ASCO Annual Meeting

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD